Publications by authors named "Barbara Conley"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

135

Total Likes

141

Extended Reach

487,907

Social Features

64
I
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, Robert Gray, Victoria Wang, Barbara A Conley

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Vismodegib in Patients With or -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Anne S Tsao, Zihe Song, Alan L Ho, Janice M Mehnert, Percy Ivy, Barbara A Conley

JCO Precis Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.
Linda K Zane, Laura M Yee, Ting-Chia Chang, Jeffrey Sklar, Guangxiao Yang, Barbara A Conley

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CB Inhibitor GSK2636771 in Cancers With Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, Panagiotis A Konstantinopoulos, Funda Meric-Bernstam, Barbara A Conley

JCO Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
Mohamed A Gouda, Zihan Wei, Jordi Rodon, Michael A Davies, Filip Janku, Barbara A Conley

JCO Precis Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, Angela M DeMichele, Richard Piekarz, Barbara A Conley

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Sunitinib in Tumors With Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
Lilian T Gien, Zihe Song, Andrew Poklepovic, Eric A Collisson, James A Zwiebel, Barbara A Conley

JCO Precis Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Defactinib (VS6063) in Patients With Tumors With Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, James A Zwiebel, Robert J Gray, Barbara A Conley

JCO Precis Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Afatinib in Patients With -Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.
Scott N Gettinger, Zihe Song, Karen L Reckamp, Jeffrey A Moscow, Robert J Gray, Barbara A Conley

JCO Precis Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell, Barbara A Conley

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Barbara A Conley

JCO Precis Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NCI-MATCH trial: lessons for precision oncology.
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, Alice P Chen, Shuli Li, Barbara A Conley

Nat Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Amy S Clark, Fangxin Hong, Richard S Finn, Angela M DeMichele, Edith P Mitchell, Barbara A Conley

Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trametinib in Patients With , , or -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
Kari B Wisinski, Yael Flamand, Melissa A Wilson, Jason J Luke, Hussein A Tawbi, Barbara A Conley

JCO Precis Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative.
Oluwadamilola Olaku, Barbara A Conley, S Percy Ivy, Lisa M McShane, Louis M Staudt

Transl Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
Philippe L Bedard, Shuli Li, Kari B Wisinski, Eddy S Yang, Sewanti A Limaye, Barbara A Conley

JCO Precis Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Copanlisib in Patients With Tumors With Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, Edith P Mitchell, John J Wright, Barbara A Conley

J Clin Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Taselisib in -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, Josh D Lauring, Edith P Mitchell, Barbara A Conley

JCO Precis Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Outcomes in Codon 12/13 and Codon 61 -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with -Mutated Tumors.
James M Cleary, Victoria Wang, Rebecca S Heist, E Scott Kopetz, Edith P Mitchell, Barbara A Conley

Clin Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, Jasgit C Sachdev, Edith P Mitchell, Barbara A Conley

JAMA Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.
David A Wheeler, Naoko Takebe, Toshinori Hinoue, Katherine A Hoadley, Maria F Cardenas, Barbara A Conley

Cancer Cell· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Keith T Flaherty, Robert J Gray, Alice P Chen, Shuli Li, Lisa M McShane, Barbara A Conley

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial.
Alice Chen, Keith Flaherty, Peter J O'Dwyer, Bruce Giantonio, Donna M Marinucci, Barbara Conley

JCO Precis Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis